cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Amicus Therapeutics Inc
11 own
23 watching
Current Price
$13.25
$-0.26
(-1.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
3,721.75M
52-Week High
52-Week High
13.615
52-Week Low
52-Week Low
5.91
Average Volume
Average Volume
1.66M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization3,721.75M
icon52-Week High13.615
icon52-Week Low5.91
iconAverage Volume1.66M
iconDividend Yield--
iconP/E Ratio--
What does the Amicus Therapeutics Inc do?
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Read More
How much money does Amicus Therapeutics Inc make?
News & Events about Amicus Therapeutics Inc.
Globe Newswire
1month ago
CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data CHMP Recommends Label for Long-Term Enzyme Replacement Therapy in Combination with Miglustat for both ERT-Experienced and Treatment-Nave Adults Living with Late-Onset Pompe Disease CHMP Opinion...
Ticker Report
1month ago
StockNews.com lowered shares of Amicus Therapeutics (NASDAQ:FOLD Get Rating) from a buy rating to a hold rating in a report released on Wednesday morning. Separately, Morgan Stanley upped their price target on Amicus Therapeutics from $14.00 to $15.00 and gave the stock an equal weight ...
Ticker Report
2 months ago
Amicus Therapeutics, Inc. (NASDAQ:FOLD Get Rating) Investment analysts at SVB Leerink reduced their Q4 2023 earnings per share (EPS) estimates for shares of Amicus Therapeutics in a note issued to investors on Monday, November 7th. SVB Leerink analyst J. Schwartz now expects that the...
Globe Newswire
3 months ago
PHILADELPHIA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided an EU regulatory update for AT-GAA. Earlier this morning, the Committee for...
Zolmax
7 months ago
Amicus Therapeutics, Inc. (NASDAQ:FOLD Get Rating) COO Bradley L. Campbell sold 16,410 shares of the firms stock in a transaction that occurred on Tuesday, June 21st. The stock was sold at an average price of $10.00, for a total transaction of $164,100.00. Following the transaction, ...
Frequently Asked Questions
Frequently Asked Questions
What is Amicus Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Amicus Therapeutics Inc shares?
plus_minus_icon
How can I buy Amicus Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Amicus Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Amicus Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Amicus Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Amicus Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Amicus Therapeutics Inc?
plus_minus_icon
What percentage is Amicus Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Amicus Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$13.25
$-0.26
(-1.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
$33.51
$-0.58 (-1.70 %)
Revance Therapeutics Inc
Revance Therapeutics Inc
$34.92
$-0.35 (-0.99 %)
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc.
$52.57
$-1.69 (-3.11 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$45.65
$-3.41 (-6.95 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
$33.51
$-0.58 (-1.70 %)
Revance Therapeutics Inc
Revance Therapeutics Inc
$34.92
$-0.35 (-0.99 %)
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc.
$52.57
$-1.69 (-3.11 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$45.65
$-3.41 (-6.95 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00